FibroGen Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

FibroGenDie Umsatzerlöse des Unternehmens werden voraussichtlich um 4.4% pro Jahr zurückgehen, während die jährlichen Gewinne voraussichtlich um 27.1% pro Jahr wachsen werden. Der Gewinn pro Aktie wird voraussichtlich um 38.8% pro Jahr wachsen.

Wichtige Informationen

27.1%

Wachstumsrate der Gewinne

38.8%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	0%
Wachstumsrate der Einnahmen	-4.4%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	09 Aug 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Gewinn- und Umsatzwachstumsprognosen

BMV:FGEN * - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	161	-77	N/A	N/A	2
12/31/2025	150	-90	N/A	N/A	2
12/31/2024	174	-90	N/A	N/A	2
6/30/2024	174	-168	-203	-202	N/A
3/31/2024	167	-240	-275	-273	N/A
12/31/2023	148	-284	-318	-315	N/A
9/30/2023	155	-294	-352	-349	N/A
6/30/2023	131	-322	-319	-317	N/A
3/31/2023	116	-307	-242	-239	N/A
12/31/2022	141	-294	-185	-146	N/A
9/30/2022	123	-362	-188	-148	N/A
6/30/2022	263	-220	-118	-52	N/A
3/31/2022	258	-281	-112	-46	N/A
12/31/2021	235	-290	-112	-82	N/A
9/30/2021	284	-215	-66	-34	N/A
6/30/2021	172	-231	-85	-80	N/A
3/31/2021	190	-183	92	96	N/A
12/31/2020	176	-189	78	82	N/A
9/30/2020	119	-229	40	44	N/A
6/30/2020	108	-311	13	18	N/A
3/31/2020	257	-110	-166	-161	N/A
12/31/2019	257	-77	-84	-79	N/A
9/30/2019	357	42	-58	-51	N/A
6/30/2019	353	49	-22	-15	N/A
3/31/2019	205	-90	-28	-22	N/A
12/31/2018	213	-86	-84	-76	N/A
9/30/2018	136	-141	-68	-60	N/A
6/30/2018	147	-123	-97	-87	N/A
3/31/2018	133	-132	N/A	-71	N/A
12/31/2017	131	-121	N/A	-67	N/A
9/30/2017	132	-121	N/A	-84	N/A
6/30/2017	122	-121	N/A	-67	N/A
3/31/2017	181	-64	N/A	-3	N/A
12/31/2016	183	-58	N/A	7	N/A
9/30/2016	172	-79	N/A	-14	N/A
6/30/2016	162	-100	N/A	-50	N/A
3/31/2016	193	-67	N/A	6	N/A
12/31/2015	181	-86	N/A	-19	N/A
9/30/2015	172	-85	N/A	-3	N/A
6/30/2015	167	-79	N/A	4	N/A
3/31/2015	136	-98	N/A	-4	N/A
12/31/2014	138	-60	N/A	22	N/A
9/30/2014	134	-24	N/A	24	N/A
6/30/2014	191	43	N/A	128	N/A
3/31/2014	117	-5	N/A	30	N/A
12/31/2013	102	-15	N/A	26	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: FGEN * wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: FGEN * wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: FGEN * wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: FGEN *Die Einnahmen des Unternehmens werden in den nächsten 3 Jahren voraussichtlich zurückgehen (-4.4% pro Jahr).

Hohe Wachstumseinnahmen: FGEN *Die Einnahmen des Unternehmens werden in den nächsten drei Jahren voraussichtlich zurückgehen (-4.4% pro Jahr).

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von FGEN * in 3 Jahren voraussichtlich hoch sein wird

FibroGen Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Forecast to breakeven in 2025

Recent updates

FibroGen, Inc. to Report Q3, 2024 Results on Nov 12, 2024

FibroGen Receives Nasdaq Notification of Non-Compliance with Minimum Bid Price Requirement

New minor risk - Shareholder dilution

Second quarter 2024 earnings released: US$0.16 loss per share (vs US$0.90 loss in 2Q 2023)

FibroGen, Inc. Announces Topline Results from Two Late-Stage Pamrevlumab Pancreatic Cancer Studies

FibroGen, Inc. to Report Q2, 2024 Results on Aug 06, 2024

FibroGen, Inc.(NasdaqGS:FGEN) dropped from Russell 3000 Index

Senior VP & Chief Medical Officer recently bought Mex$486k worth of stock

FibroGen, Inc. Announces FDA Clearance of Investigational New Drug Application for FG-3165, A Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors

FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer at the 2024 American Society of Clinical Oncology Annual Meeting

First quarter 2024 earnings released: US$0.33 loss per share (vs US$0.81 loss in 1Q 2023)

Insufficient new directors

FibroGen, Inc. to Report Q1, 2024 Results on May 06, 2024

FibroGen, Inc. to Present Clinical Data from Dose Escalation Phase 1B Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer at 2024 American Society of Clinical Oncology Annual Meeting

Hangzhou Andao Pharmaceutical Ltd. and Kind Pharmaceuticals Announce Settlement with FibroGen, Inc

Insufficient new directors

Fibrogen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer

CEO & Director recently bought Mex$1.6m worth of stock

FibroGen Appoints Deyaa Adib as Senior Vice President and Chief Medical Officer

Full year 2023 earnings released: US$2.92 loss per share (vs US$3.14 loss in FY 2022)

FibroGen, Inc. to Report Q4, 2023 Results on Feb 26, 2024

New major risk - Financial position

Insufficient new directors

FibroGen, Inc. Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network’s Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic Cancer

Insufficient new directors

FibroGen, Inc. Receives Non-Compliance Letter from Nasdaq Related to Minimum Bid Price

FibroGen, Inc. Receives Non-Compliance Letter from Nasdaq Related to Minimum Bid Price

FibroGen, Inc. to Report Q3, 2023 Results on Nov 06, 2023

FibroGen, Inc. Appoints Thane Wettig as Chief Executive Officer

Mark Eisner Resigns as Chief Medical Officer of Fibrogen, Inc., Effective September 8, 2023

Insufficient new directors

Fibrogen, Inc. Announces Topline Results from Lelantos-2, A Phase 3 Clinical Study of Pamrevlumab in Ambulatory Muscular Dystrophy

Second quarter 2023 earnings released: US$0.90 loss per share (vs US$0.78 loss in 2Q 2022)

Fibrogen, Inc. Announces Chief Executive Officer Changes

FibroGen, Inc. to Report Q2, 2023 Results on Aug 07, 2023

FibroGen, Inc. Announces Topline Results from LELANTOS-1 Phase 3 Clinical Study of Pamrevlumab in Non-Ambulatory Patients with Duchenne Muscular Dystrophy

FibroGen, Inc. Announces Positive Topline Results from China Pivotal Phase 3 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced Anemia

Insider recently sold Mex$2.2m worth of stock

FibroGen, Inc. to Report Q4, 2022 Results on Feb 27, 2023

CEO & Director recently sold Mex$589k worth of stock

CEO & Director recently sold Mex$589k worth of stock

Executive VP & Chief Commercial Officer recently sold Mex$225k worth of stock

Third quarter 2022 earnings released: US$0.98 loss per share (vs US$0.54 profit in 3Q 2021)

FibroGen, Inc. to Report Q3, 2022 Results on Nov 07, 2022

FibroGen Announces Completion of Patient Enrollment in MATTERHORN, a Phase 3 Clinical Study of Roxadustat for the Treatment of Anemia in Patients with Lower Risk Transfusion-Dependent Myelodysplastic Syndromes

FibroGen Announces Completion of Patient Enrollment in MATTERHORN, a Phase 3 Clinical Study of Roxadustat for the Treatment of Anemia in Patients with Lower Risk Transfusion-Dependent Myelodysplastic Syndromes

Second quarter 2022 earnings released: US$0.78 loss per share (vs US$1.45 loss in 2Q 2021)

FibroGen, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Fibrogen Announces Completion of Patient Enrollment in LELANTOS-2, A Phase 3 Clinical Study of pamrevlumab in Duchenne Muscular Dystrophy

FibroGen, Inc., Annual General Meeting, Jun 16, 2022

FibroGen, Inc. to Report Q1, 2022 Results on May 09, 2022

FibroGen, Inc. Announces Completion of Patient Enrollment in ZEPHYRUS-1, a Phase 3 Clinical Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

FibroGen, Inc. to Report Q4, 2021 Results on Feb 28, 2022

Third quarter 2021 earnings released: EPS US$0.54 (vs US$0.36 in 3Q 2020)

Independent Director recently sold Mex$3.0m worth of stock

Chief Commercial Officer recently bought Mex$727k worth of stock

FibroGen, Inc. Announces Positive Topline Results from Phase 2 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced Anemia

Astellas Receives EC Approval for First-Inclass Evrenzo (Roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease

Second quarter 2021 earnings released: US$1.45 loss per share (vs US$0.95 loss in 2Q 2020)

FibroGen, Inc. Announces Outcome of FDA Advisory Committee Review of Roxadustat

Independent Director Kalevi Kurkijärvi has left the company

Astellas Receives Positive CHMP Opinion for Evrenzo™ (Roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease

Scott+Scott Attorneys At Law LLP Reminds Investors of Securities Class Action Against Fibrogen, Inc

Forecast to breakeven in 2025

First quarter 2021 earnings released: US$0.78 loss per share (vs US$0.89 loss in 1Q 2020)

The Schall Law Firm and Roche Freedman LLP Files Securities Class Action Suit with Extended Class Period Against FibroGen, Inc

Bernstein Litowitz Berger & Grossmann LLP Announces the Filing of Securities Class Action Lawsuit Against Fibrogen, Inc

Rosen Law Firm Announces the Filing of a Class Action Lawsuit on Behalf of Purchasers of the Securities of FibroGen, Inc

FibroGen, Inc. Initiates LELANTOS-2 – Second Phase 3 Clinical Study of Pamrevlumab for the Treatment of Duchenne Muscular Dystrophy

Executive Advisor to Chief Executive Officer K. Yu has left the company

Full year 2020 earnings released: US$2.11 loss per share (vs US$0.89 loss in FY 2019)

Revenue misses expectations

FibroGen, Inc. to Report Q4, 2020 Results on Mar 01, 2021